Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomised 2*2 Factorial Design Comparing Standard to Reduced-target Volume Radiotherapy With or Without All-trans Retinoic Acid (ATRA) in Patients With Lateralised Oropharyngeal, Laryngeal and Hypopharyngeal Squamous Cell Carcinoma.

NCT06706401 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT06706401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06706401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomised 2*2 Factorial Design Comparing Standard to Reduced-target Volume Radiotherapy With or Without All-trans Retinoic Acid (ATRA) in Patients With Lateralised Oropharyngeal, Laryngeal and Hypopharyngeal Squamous Cell Carcinoma.
Lead sponsor
Centre Leon Berard
Phase
Phase 3
Overall status
Recruiting
Start date
February 20, 2025
Completion date
January 31, 2029
Enrollment
460 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hypopharynx cancer, larynx cancer, oropharynx cancer, primary head and neck tumor